THE PRESENCE OF M2 MACROPHAGES IN OVARIAN CANCER IS INFLUENCED BY TUMOR STAGE AND GRADE, NOT BY THE ADMINISTRATION OF PACLITAXEL-CARBOPLATIN: A PILOT STUDY

被引：0
|
作者：
Baert, T. [1 ]
Mathivet, T. [2 ]
Van Hoylandt, A. [3 ]
Vergote, I. [1 ]
Coosemans, A. [1 ]
机构：
[1] Univ Hosp Leuven, Gynaecol & Obstet, Leuven, Belgium
[2] Katholieke Univ Leuven, Vesalius Res Ctr, Dept Oncol, Lab Vasc Patterning, Leuven, Belgium
[3] Katholieke Univ Leuven, Dept Oncol, Lab Gynaecol Oncol, Leuven, Belgium
来源：
INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER | 2015年 / 25卷 / 09期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
ESGO-1130
引用
收藏
页码：1282 / 1282
页数：1
相关论文
共 50 条
  • [41] Cardamonin suppresses pro-tumor function of macrophages by decreasing M2 polarization on ovarian cancer cells via mTOR inhibition
    Chen, Huajiao
    Huang, Sheng
    Niu, Peiguang
    Zhu, Yanting
    Zhou, Jintuo
    Jiang, Li
    Li, Danyun
    Shi, Daohua
    MOLECULAR THERAPY-ONCOLYTICS, 2022, 26 : 175 - 188
  • [42] Ovarian cancer derived extracellular vesicles promote the cancer progression and angiogenesis by mediating M2 macrophages polarization
    Tang, Xue
    Ma, Chengbin
    Wu, Qiongwei
    Yu, Meng
    JOURNAL OF OVARIAN RESEARCH, 2024, 17 (01)
  • [43] A multicenter randomized trial of paclitaxel (175 mg/m2) plus carboplatin (6AUC) versus paclitaxel (225 mg/m2) plus carboplatin (6AUC) in advanced non-small cell lung cancer (NSCLC)
    Kosmidis, PA
    Mylonakis, N
    Skarlos, D
    Samantas, E
    Demopoulos, MA
    Papadimitriou, C
    Kalophonos, C
    Pavlidis, N
    Papakonstantinou, C
    Fountzilas, G
    EUROPEAN JOURNAL OF CANCER, 1999, 35 : S247 - S247
  • [44] Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: A Gynecologic Oncology Group study
    Ozols, RF
    Bundy, BN
    Greer, BE
    Fowler, JM
    Clarke-Pearson, D
    Burger, RA
    Mannel, RS
    DeGeest, K
    Hartenbach, EM
    Baergen, R
    JOURNAL OF CLINICAL ONCOLOGY, 2003, 21 (17) : 3194 - 3200
  • [45] Infiltration of MDR1 Positive M2 Macrophages Leads to Worse Prognosis in Ovarian Cancer
    Badmann, Susann
    Heublein, Sabine
    Mayr, Doris
    Liao, Yue
    Kolben, Thomas
    Beyer, Susanne
    Hester, Anna
    Zeder-Goess, Christine
    Burges, Alexander
    Mahner, Sven
    Jeschke, Udo
    Trillsch, Fabian
    Czogalla, Bastian
    ONCOLOGY RESEARCH AND TREATMENT, 2020, 43 : 227 - 228
  • [46] Veliparib with carboplatin and paclitaxel in frontline high-grade serous ovarian cancer (HGSOC): Efficacy and safety of paclitaxel weekly and every 3 weeks in the VELIA study
    Okamoto, A.
    Fleming, G.
    Bookman, M.
    Brady, M. F.
    Swisher, E. M.
    Steffensen, K. D.
    Cloven, N. G.
    Enomoto, T.
    O'Malley, D. M.
    Van Le, L.
    Tewari, K. S.
    Barlin, J. N.
    Bradley, W.
    Moore, K. N.
    Chan, J.
    Wu, M.
    Hashiba, H.
    Dinh, M. H.
    Coleman, R. L.
    Aghajanian, C.
    ANNALS OF ONCOLOGY, 2020, 31 : S618 - S618
  • [47] GOG 175: A Randomized phase III trial of IV carboplatin (AUC 6) and paclitaxel 175 mg/m2 Q 21 days x 3 courses plus low-dose paclitaxel 40 mg/m2/wk versus IV carboplatin (AUC 6) and paclitaxel 175 mg/m2 Q 21 days x 3 courses plus observation in patients with early-stage ovarian carcinoma
    Mannel, R.
    Brady, M.
    Kohn, E.
    Hanjani, P.
    Hiura, M.
    Lee, R.
    De Geest, K.
    Cohn, D.
    Monk, B.
    Michael, H.
    GYNECOLOGIC ONCOLOGY, 2010, 116 (03) : S2 - S2
  • [48] Phase I and pharmacologic study of the combination paclitaxel and carboplatin as first-line chemotherapy in stage III and IV ovarian cancer
    Huizing, MT
    vanWarmerdam, LJC
    Rosing, H
    Schaefers, MCW
    Lai, A
    Helmerhorst, TJM
    Veenhof, CHN
    Birkhofer, MJ
    Rodenhuis, S
    Beijnen, JH
    tenBokkelHuinink, WW
    JOURNAL OF CLINICAL ONCOLOGY, 1997, 15 (05) : 1953 - 1964
  • [49] Expression of the Homeobox Gene HOXA9 in Ovarian Cancer Induces Peritoneal Macrophages to Acquire an M2 Tumor-Promoting Phenotype
    Ko, Song Yi
    Ladanyi, Andras
    Lengyel, Ernst
    Naora, Honami
    AMERICAN JOURNAL OF PATHOLOGY, 2014, 184 (01): : 271 - 281
  • [50] High MUC2 Expression in Ovarian Cancer Is Inversely Associated with the M1/M2 Ratio of Tumor-Associated Macrophages and Patient Survival Time
    He, Yi-feng
    Zhang, Mei-ying
    Wu, Xin
    Sun, Xiang-jun
    Xu, Ting
    He, Qi-zhi
    Di, Wen
    PLOS ONE, 2013, 8 (12):
12345